Cronos Group Inc. Announces Director Changes and Executive Compensation

Ticker: CRON · Form: 8-K · Filed: 2024-04-03T00:00:00.000Z

Sentiment: neutral

Topics: director-change, executive-compensation, governance

TL;DR

Cronos Group board shakeup: Murphy out, Esra in. Executive pay details also disclosed.

AI Summary

Cronos Group Inc. announced on April 1, 2024, the departure of Director Michael G. Murphy and the appointment of Dr. Zena S. Esra as a new director. Additionally, the company reported on compensatory arrangements for its named executive officers and other events.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Director changes and executive compensation disclosures can sometimes precede or reflect significant strategic shifts or internal challenges within a company.

Key Players & Entities

FAQ

Who has departed from the Cronos Group Inc. board of directors?

Michael G. Murphy has departed from the Cronos Group Inc. board of directors.

Who has been appointed as a new director to the Cronos Group Inc. board?

Dr. Zena S. Esra has been appointed as a new director to the Cronos Group Inc. board.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is April 1, 2024.

What are the main items reported in this 8-K filing?

This 8-K filing reports the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and other events.

What is the principal executive office address for Cronos Group Inc.?

The principal executive office address for Cronos Group Inc. is 111 Peter Street, Suite 300, Toronto, Ontario M5V 2H1.

From the Filing

0001656472-24-000045.txt : 20240403 0001656472-24-000045.hdr.sgml : 20240403 20240403163630 ACCESSION NUMBER: 0001656472-24-000045 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 36 CONFORMED PERIOD OF REPORT: 20240401 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cronos Group Inc. CENTRAL INDEX KEY: 0001656472 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38403 FILM NUMBER: 24819414 BUSINESS ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2H1 BUSINESS PHONE: (416) 504-0004 MAIL ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2H1 FORMER COMPANY: FORMER CONFORMED NAME: PharmaCan Capital Corp. DATE OF NAME CHANGE: 20151021 8-K 1 cron-20240401.htm 8-K cron-20240401 false CRONOS GROUP INC. 0001656472 Toronto Canada 001-38403 Ontario 0001656472 2024-04-01 2024-04-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 CRONOS GROUP INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38403 N/A (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 111 Peter Street, Suite 300 Toronto , Ontario M5V 2H1 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 416 ) 504-0004 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class  Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value CRON The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of April 2, 2024, Cronos Group Inc. (the “Company”) and Cronos Israel G.S. Cultivation Ltd. (“Cronos Israel”) entered into an Amended and Restated Executive Employment Agreement (the “Gorelik Employment Agreement”) with Ran Gorelik, pursuant to which Mr. Gore

View on Read The Filing